Sichenzia Ross Ference Carmel LLP Represents Virpax Pharmaceuticals in $6 Million Public Offering

New York, NY – January 28, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, in its $6 million public offering.
Spartan Capital Securities, LLC acted as the sole placement agent for the offering. The Spartan Capital team was led by Stephen Faucetta and Brian Duddy.
The SRFC team was led by partner Ross Carmel and associate Benjamin Sklar.